Drug Search Results
More Filters [+]

Arformoterol

Alternative Names: arformoterol, brovana
Latest Update: 2023-09-21
Latest Update Note: News Article

Product Description

Arformoterol inhalation is used to control wheezing, shortness of breath, coughing, and chest tightness caused by chronic obstructive pulmonary disease (COPD; a group of lung diseases, which includes chronic bronchitis and emphysema). Arformoterol is in a class of medications called long-acting beta agonists (LABAs). It works by relaxing and opening air passages in the lungs, making it easier to breathe. (Sourced from: https://medlineplus.gov/druginfo/meds/a607061.html)

Mechanisms of Action: ADRB2 Agonist,LAB Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral,Inhalant

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Bangladesh | India | Turkey | United States

Approved Indications: Asthma | Bronchitis | Bronchitis, Chronic | Chronic Obstructive Pulmonary Disease | Pulmonary Emphysema

Known Adverse Events: Back Pain | Chest Pain | Pain Unspecified | Sinusitis | Dyspnea | Diarrhea | Edema

Company: Changtai Pharmaceutical
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Arformoterol

Countries in Clinic: China

Active Clinical Trial Count: 3

Highest Development Phases

Phase 3: Chronic Obstructive Pulmonary Disease

Phase 1: Asthma|Bronchitis, Chronic|Dyspnea|Emphysema|Kidney Diseases|Lung Diseases, Obstructive

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CTR20211924

P3

Not yet recruiting

Chronic Obstructive Pulmonary Disease

None

CTR20210048

P1

Not yet recruiting

Bronchitis, Chronic|Kidney Diseases|Emphysema|Dyspnea|Asthma|Lung Diseases, Obstructive

None

CTR20222650

P3

Not yet recruiting

Chronic Obstructive Pulmonary Disease

None

Recent News Events